The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Family Screening in Hypertrophic Cardiomyopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and 24% and 37% in relatives with positive genetics.”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“compared with 18% in relatives of probands with genotype positive hypertrophic cardiomyopathy”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the prevalence of hypertrophic cardiomyopathy in relatives of patients with gene elusive disease is less than in those with gene positive disease.”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies report hypertrophic cardiomyopathy prevalences of 5% and 12% among living relatives within three generations of probands with gene elusive hypertrophic cardiomyopathy”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Research works printed but not linked: 29
- Maron, 1994, Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study, Am J Cardiol, 73, 577, 10.1016/0002-9149(94)90337-9 · DOI
- Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 · DOI
- Brock, 1957, Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis, Guys Hosp Rep, 106, 221
- Teare, 1958, Asymmetrical hypertrophy of the heart in young adults, Br Heart J, 20, 1, 10.1136/hrt.20.1.1 · DOI
- Geske, 2018, Hypertrophic cardiomyopathy: clinical update, JACC Heart Fail, 6, 364, 10.1016/j.jchf.2018.02.010 · DOI
- Richard, 2003, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 · DOI
- Charron, 2010, Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 31, 2715, 10.1093/eurheartj/ehq271 · DOI
- Arbelo, 2023, 2023 ESC guidelines for the management of cardiomyopathies, Eur Heart J, 44, 3503, 10.1093/eurheartj/ehad194 · DOI · Paper page
- Ho, 2015, Genetic advances in sarcomeric cardiomyopathies: state of the art, Cardiovasc Res, 105, 397, 10.1093/cvr/cvv025 · DOI
- Teekakirikul, 2013, Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era, J Mol Diagn, 15, 158, 10.1016/j.jmoldx.2012.09.002 · DOI
- Neubauer, 2019, Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry, J Am Coll Cardiol, 74, 2333, 10.1016/j.jacc.2019.08.1057 · DOI
- Ommen, 2021, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Thorac Cardiovasc Surg, 162, e23, 10.1016/j.jtcvs.2021.04.001 · DOI
- Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
- Miller, 2023, ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG), Genet Med, 25, 10.1016/j.gim.2023.100866 · DOI
- Nielsen, 2023, Patients with hypertrophic cardiomyopathy and normal genetic investigations have few affected relatives, J Am Coll Cardiol, 82, 1751, 10.1016/j.jacc.2023.08.041 · DOI · Paper page
- Christiaans, 2011, Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy, Eur Heart J, 32, 1161, 10.1093/eurheartj/ehr092 · DOI · Paper page
- van Velzen, 2018, Outcomes of contemporary family screening in hypertrophic cardiomyopathy, Circ Genom Precis Med, 11, 10.1161/CIRCGEN.117.001896 · DOI · Paper page
- Alfares, 2015, Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity, Genet Med, 17, 880, 10.1038/gim.2014.205 · DOI · Paper page
- Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 · DOI · Paper page
- Liantonio, 2023, Brugada syndrome: more than a monogenic channelopathy, Biomedicines, 11, 10.3390/biomedicines11082297 · DOI
- Chumakova, 2023, Advanced searching for hypertrophic cardiomyopathy heritability in real practice tomorrow, Front Cardiovasc Med, 10, 10.3389/fcvm.2023.1236539 · DOI
- Alfakih, 2003, Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences, J Magn Reson Imaging, 17, 323, 10.1002/jmri.10262 · DOI
- Lorenz, 1999, Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging, J Cardiovasc Magn Reson, 1, 7, 10.3109/10976649909080829 · DOI · Paper page
- Lakdawala, 2021, Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic cardiomyopathy, Circ Genom Precis Med, 14, 10.1161/CIRCGEN.120.003062 · DOI
- Jacobsen, 2023, Long term mortality in patients with hypertrophic cardiomyopathy—a Danish nationwide study, American Heart J Plus, 25
- de Marvao, 2021, Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 1097, 10.1016/j.jacc.2021.07.017 · DOI
- Vissing, 2022, Family screening in dilated cardiomyopathy: prevalence, incidence, and potential for limiting follow-up, JACC Heart Fail, 10, 792, 10.1016/j.jchf.2022.07.009 · DOI
- Vissing, 2023, Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial, JAMA Cardiol, 8, 1083, 10.1001/jamacardio.2023.2808 · DOI
- Garmany, 2023, Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care, ESC Heart Fail, 10, 1919, 10.1002/ehf2.14345 · DOI
Cited by
Sorted by citations
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Metadata
- Authors
- Silajdzija, E., Vissing, C. R., Christensen, E. B., Mills, H. L., Kock, T. O., Andersen, L. J., Snoer, M., Thune, J. J., Bartels, E. D., Axelsson Raja, A., Christensen, A. H., & Bundgaard, H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 84
- Issue
- 19
- Pages
- 1854-1865
- ISSN
- 0735-1097
- Cited by
- 17
- References
- 1
- Language
- en
- Licence
- Funders
- Rigshospitalet
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Family Screening in Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jacc.2024.08.011
- The paper
- Silajdzija, E., Vissing, C. R., Christensen, E. B., Mills, H. L., Kock, T. O., Andersen, L. J., Snoer, M., Thune, J. J., Bartels, E. D., Axelsson Raja, A., Christensen, A. H., & Bundgaard, H. (2024). Family Screening in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.08.011
